Neutrophilic drug eruptions (Q33944685)

30 July 2017

1 reference

title

Neutrophilic drug eruptions (English)

1 reference

30 July 2017

Roujeau JC

1

1 reference

30 July 2017

publication date

1 May 2000

1 reference

30 July 2017

published in

Clinics in Dermatology

1 reference

30 July 2017

volume

18

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

331-337

1 reference

Sweet's syndrome: systemic signs and symptoms and associated disorders

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

The incidence of Sweet's syndrome in Geneva. A retrospective study of 29 cases

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Sweet syndrome in a child with aplastic anemia receiving recombinant granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Drug-induced Sweet's syndrome (acute febrile neutrophilic dermatosis) associated with hydralazine

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Acute neutrophilic dermatosis with myeloblastic infiltrate in a leukemia patient receiving all-trans-retinoic acid therapy

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Leukocyte colony-stimulating factors. A review of associated neutrophilic dermatoses and vasculitides

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Lymphoedema-area-restricted Sweet syndrome during G-CSF treatment

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Neutrophilic dermatoses in HIV infection

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Pyoderma gangrenosum in immunosuppressed patients

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Hydralazine-induced systemic lupus erythematosus presenting as pyoderma gangrenosum — like ulcers

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Development of folliculitis and pyoderma gangrenosum in association with abdominal pain in a patient following treatment with isotretinoin

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Pyoderma gangrenosum following treatment with isotretinoin

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Vegetating iodides after an intravenous pyelogram

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Vegetating iododerma with underlying systemic diseases: report of three cases

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Iododerma after computed tomographic scan with intravenous radiopaque contrast media

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

GENERALIZED PUSTULAR PSORIASIS

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Acute generalized exanthematous pustulosis. Analysis of 63 cases

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Generalised pustular drug rash.

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Subcorneal pustular dermatosis

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Pustular vasculitis of the hands

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS).

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Human parvovirus B19-induced vesiculopustular skin eruption

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

A localized, recurrent pustular eruption following amoxycillin administration

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Toxic pustuloderma associated with azithromycin

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Pustular eruptions following administration of cefazolin: a possible interaction with methyldopa

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Pustular eruption following administration of cefazolin: a second case report

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Generalized eruptive pustular drug rash due to cephalexin.

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Generalized pustular dermatosis caused by isoniazid

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Acute generalized exanthematous pustulosis due to doxycycline

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Pustular dermatosis induced by co-trimoxazole

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Pustular psoriasis associated with hydroxychloroquine

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Acute generalized exanthematous pustulosis induced by terbinafine

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Terbinafine-induced acute generalized exanthematous pustulosis confirmed by a positive patch-test result

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Acute generalized exanthematous pustulosis, induced by nystatin

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Acute generalized exanthematous pustulosis: a cutaneous adverse effect due to prophylactic antiviral therapy with protease inhibitor

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Acute generalized exanthematous pustulosis induced by paracetamol. A case with severe hemodynamic disturbances

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Acute generalized exanthematous pustulosis associated with paracetamol

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Acute generalized exanthematous pustular dermatitis induced by diltiazem

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Acute generalized exanthematous pustulosis induced by dexamethasone injection

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Pustular reactions to hexafluorosilicate in foam rubber

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016/S0738-081X(99)00124-8

7 January 2021

10.1016/S0738-081X(99)00124-8

Identifiers

DOI

1 reference

30 July 2017

1 reference